Table 6.55Adverse events

AEs assessment outcomeReferenceInterventionAssessment timeOutcome/effect size
Number of patients with AEs1 MA (McCarthy et al. 2006) 1 RCT (Pipitone and Scott 2001), N=75PEMF vs placebo PEMF6 weeks (end of treatment)2.7% (PEMF) and 5.3% placebo PEMF
Favours PEMF
Adverse skin reactions1 MA (Hulme et al. 2002) 1 RCT, N=71PEMF vs placebo PEMF4 weeks and 1 monthNS
Number of patients with mild AEs1 MA (McCarthy et al. 2006) 1 RCT (Thamsborg et al. 2005), N=90PEMF vs placebo PEMF2 weeks (mid- teatment)13.3% (PEMF) and 6.7% (placebo PEMF)
Placebo better

From: 6, Non-pharmacological management of osteoarthritis

Cover of Osteoarthritis
Osteoarthritis: National Clinical Guideline for Care and Management in Adults.
NICE Clinical Guidelines, No. 59.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.